KLF17P2

Across TCGA pan-cancer cohorts, KLF17P2 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of KLF17P2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where KLF17P2 RNA is repressed in tumor relative to normal tissue. In most cancer types KLF17P2 is over-expressed in tumor, although a few such as KIRC and BRCA show the opposite, repressed pattern.

KIRC, BRCA, and KIRP are the cancer types where KLF17P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KLF17P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.072	<.001	6	view →
BRCA	Female	II,III,IV	−0.103	<.001	4	view →
KIRP	Female	II,III,IV	+0.142	.044	2	view →
PRAD	All	All	−0.044	.046	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

KLF17P2–KIRC

Open the KIRC breakdown →